Navigation Links
Press registration open for ASM Biodefense and Emerging Diseases Research Meeting

The American Society for Microbiology (ASM) will host its 2013 Biodefense and Emerging Diseases Research Meeting February 25-27, 2013 at the Marriott Wardman Park Hotel in Washington, DC.

The purpose of this meeting is to bring together individuals who are carrying out research to defend against the threat of bioterrorism with decision makers shaping the future biodefense research agenda, recognizing that emerging infectious diseases serve as a paradigm for handling the public threat of bioterrorism.

This meeting is intended for scientists, public health researchers and policy makers who need to be informed about the latest scientific developments. The meeting will include a series of keynote addresses by leaders in the field of biodefense and poster sessions presenting up-to-the-minute cutting-edge research on biothreat agents, vaccines, detection and diagnostic procedures, animal and plant pathogens, global surveillance, and other vital topics.

Highlighted topics include:

  • H5N1: One Year Later
  • Bats As Sources of Emerging Infectious Diseases
  • Emergence of A New Pathogenic Coronavirus: Are We Witnessing the Beginning of Another SARS-like Pandemic, Or Not!

Meeting registration is offered complimentary to reporters covering the event. To obtain Press registration to the meeting, please email Garth Hogan (


Contact: Garth Hogan
American Society for Microbiology

Page: 1

Related biology news :

1. Imaging biomarker predicts response to rapid antidepressant
2. Depression-era drainage ditches emerge as sleeping threat to Cape Cod salt marshes
3. ACMG 2013 Clinical Genetics Meeting -- Complimentary press registration is now open
4. Cancer suppressor gene links metabolism with cellular aging
5. Press registration opens for 2013 meeting of worlds largest scientific society
6. Bullying by childhood peers leaves a trace that can change the expression of a gene linked to mood
7. Study uncovers mechanism used by BRCA1 to suppress tumors
8. Could ending your fatty food habit cause withdrawal symptoms and depression?
9. Prospectus addresses most pressing marine science questions
10. Can compressed fluids increase enzyme activity in industrial bioprocesses?
11. New antidepressant acts very rapidly and is long lasting
Post Your Comments:
(Date:8/15/2017)... 2017   ivWatch LLC , a medical device company focused ... announced receipt of its ISO 13485 Certification, the global standard for ... for Standardization (ISO®). ... 400 Continuous Monitoring device for the early detection of IV infiltrations. ... "This is an important milestone for ivWatch, ...
(Date:6/23/2017)... ITHACA, N.Y. , June 23, 2017 /PRNewswire/ ... leader in dairy research, today announced a new collaboration ... reduce the chances that the global milk supply is ... dairy project, Cornell University has become the newest academic ... Supply Chain, a food safety initiative that includes IBM ...
(Date:5/16/2017)... , May 16, 2017  Veratad Technologies, LLC ( ... online age and identity verification solutions, announced today they ... Conference 2017, May 15 thru May 17, 2017, in ... and International Trade Center. Identity impacts ... and in today,s quickly evolving digital world, defining identity ...
Breaking Biology News(10 mins):
(Date:10/12/2017)... SARASOTA, FL (PRWEB) , ... ... ... Inc. (RPS®) today announces publication of a United States multicenter, prospective clinical ... single use, disposable, point-of-care diagnostic test capable of identifying clinically significant acute ...
(Date:10/11/2017)... , ... October 11, 2017 , ... ... gene in its endogenous context, enabling overexpression experiments and avoiding the use of ... small RNA guides is transformative for performing systematic gain-of-function studies. , This ...
(Date:10/11/2017)... ROTTERDAM, the Netherlands and LAGUNA HILLS, ... that The Institute of Cancer Research, London ... will use MMprofiler™ with SKY92, SkylineDx,s prognostic tool to risk-stratify ... high-risk trial known as MUK nine . The University ... this trial, which is partly funded by Myeloma UK, and ...
(Date:10/10/2017)... (PRWEB) , ... October 10, ... ... development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed ... targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration with ...
Breaking Biology Technology: